Increased cancer risk in children of mothers with thyroid disorders
Thyroid disorders in mothers-to-be increases the risk for future thyroid cancer in the children. This is shown in a new study in the journal The Lancet Diabetes & Endocrinology where IGP researcher Ingrid Glimelius has participated.
Thyroid cancer tends to be diagnosed at a younger age compared with most other malignancies. It is therefore important to determine if there are risk factors early in life, even before birth, that affect the development of this type of cancer. In the new study the researchers have analysed medical registries from the Nordic countries and found that if the mothers have been diagnosed with a thyroid disorder before or during the pregnancy the risk for thyroid cancer increased in the children.
“We could see this increased risk for several different thyroid disorder in the mothers, both hyper- and hypothyroidism, goiter and benign tumours. I think these are alarming results, especially in light of that so many people in Sweden are treated for thyroid problems,” says Ingrid Glimelius.
The risk for the children to develop thyroid cancer later in life was also affect by factors in the babies such as high birth weight or congenital malfunction of the thyroid. If the mother had diabetes before the pregnancy also resulted in an increased risk for future thyroid cancer in the children.
The new findings should motivate additional research into early-life exposures that might cause thyroid cancer. This might help to identify modifiable risk factors and targets for primary prevention of the disease.
“We need to increase our understanding of cancer risk factors, to be able to reduced them as much as possible. For thyroid cancer we would for instance need to determine if the enhanced risk is due to treatments administrated during the pregnancy, iodine deficiency in the fetus, genetic associations or other factors,” says Ingrid Glimelius.
Rare genetic variants are not the main cause of common diseases
Although some rare variants can significantly increase the risk of disease for a few individuals, the majority of the genetic contribution to common diseases is due to a combination of many common genetic variants with small effects. This is shown by researchers at IGP and other departments at Uppsala University in a new comprehensive study published in the journal Nature Communications.
Subgroups of brain tumours associated with cell origin and disease prognosis
Researchers at IGP have detected different subgroups of the brain tumour form glioblastoma, where the cancer cells’ properties depend on which cell type they originate from. The used analysis method could also separate glioblastoma patients with significant differences in survival. The findings open up for identifying specific therapeutic targets for the new subgroups of glioblastoma.
Armed CAR-T cells to better fight cancer
Immunotherapy is increasingly becoming a successful way to treat cancer. Researchers at IGP have now developed armed CAR-T cells that reinforce the immune defence against cancer and that could increase the possibilities to successfully treat solid tumours. The study has been published in the journal Nature BioMedical Engineering.
Inflammation and net-like protein structures in cerebral cavernous malformations
In the condition known as cavernoma, lesions arise in a cluster of blood vessels in the brain, spinal cord or retina. Researchers at IGP now show in a new study that white blood cells and protein structures associated with the immune response infiltrate the vessel lesions. The findings support that inflammation has a role in the development of cavernoma and indicate a potential biomarker for the disease.
Protein landscape on cancer cells mapped with new technology
In recent years, great advances have been made in the development of new, successful immunotherapies to treat cancer. Two types of targeted immunotherapies that have revolutionised areas of cancer care are CAR T-cell therapy and antibody treatments. However, there are still significant challenges in the identification of cancer cell surface proteins that function as targets for immunotherapies. Mattias Belting, professor at Lund University and senior consultant at Skåne University Hospital, and guest professor at IGP, is well on the way and his group’s findings are now published in the journal PNAS.
CRISPR-Cas9 can generate unexpected, heritable mutations
CRISPR-Cas9, the “genetic scissors”, creates new potential for curing diseases; but treatments must be reliable. In a new study, researchers have discovered that the method can give rise to unforeseen changes in DNA that can be inherited by the next generation. These scientists therefore urge caution and meticulous validation before using CRISPR-Cas9 for medical purposes.
New technology to study DNA in archived tissue samples
Researchers at IGP have developed a technology that allows studies of DNA profiles in archived tissue samples. The technology permits investigators to better understand regulation of gene activity in cancer and precision medicine.
New genes associated with relapse of acute myeloid leukemia
In the blood cancer type acute myeloid leukemia, it is common that patients relapse some time after treatment. Researchers from IGP have in a new study identified genes that seem to be associated with the risk of relapse. The findings may form the basis for new treatment strategies and contribute to better survival for patients with acute myeloid leukemia.